摘要:
The present invention relates to torsemide having relatively small particles, and corresponding relatively large surface area. In one embodiment, the invention relates to torsemide and formulations containing torsemide having a mean particle diameter of less than 200 micrometers.
摘要:
Provided is a method of selectively enzymatically esterifying or selectively enzymatically solvolyzing epimers of analogs of vitamin D having a stereogenic center at C-24 that has a free or esterified OH group. The method can be used, for example, for separating mixed epimers of the vitamin D analog.
摘要:
Provided is a method of selectively enzymatically esterifying or selectively enzymatically solvolyzing epimers of analogs of vitamin D having a stereogenic center at C-24 that has a free or esterified OH group. The method can be used, for example, for separating mixed epimers of the vitamin D analog.
摘要:
The present invention is directed to the novel forms of torsemide, designated Form V, amorphous torsemide, Dupont Form 2 solvent adduct, Dupont Form 2 ethanol adduct and Dupont Form 2 isopropanol adduct. Methods for their preparation are also disclosed. The present invention also relates to processes for making torsemide modification (I). Pharmaceutical compositions containing the new forms of torsemide and methods of using them are also disclosed.
摘要:
The present invention is directed to a novel process for preparing Paricalcitol wherein Paricalcitol, dissolved in a solvent, is precipitated from a concentrated or seeded solution.
摘要:
Provided are novel crystalline forms of 1,24-(S)-dihydroxy vitamin D2, including hydrates and solvates, and methods for making them. Also provided are pharmaceutical and nutraceutical compositions containing the novel crystalline forms.